TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01783704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
Study: NCT03482414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaming board with two-player games
Description: upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
Study: NCT00599040

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The DASH diet with weight loss
Description: A reduced calorie diet is provided to participants based on the DASH diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The DASH diet without weight loss
Description: participants are given a weight maintainenance diet based on the DASH diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dairy diet
Description: participants are given a high dairy, reduced calorie diet
Study: NCT04453046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopurifier
Description: Two Hemopurifier treatments on Day 1 and Day 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200mg IV
Description: Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles
Study: NCT04705194

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Resection of one or more liver segments as treatment for primary or metastatic liver cancer

Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Resection of one or more liver segments as treatment for primary or metastatic liver cancer

Intervention type: PROCEDURE
Intervention: PVE or ALPPS
Description: Embolization of the portal vein feeding the diseased liver segments or surgical liver partition and portal vein ligation of the diseased liver segments in order to induce growth of the future liver remnant ahead of the resection.
Study: NCT02431572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBR PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBR PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBR PET

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cancer Immunotherapy
Description: Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cancer Immunotherapy
Description: Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation and chemotherapy
Description: Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
Study: NCT02102321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT01265550

Intervention type: DEVICE
Group type: OTHER
Intervention: Nissen fundoplication
Description: laparoscopic antireflux surgery

Intervention type: DRUG
Group type: OTHER
Intervention: baclofen
Description: Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved.

Intervention type: DRUG
Group type: OTHER
Intervention: baclofen
Description: Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved.
Study: NCT01265550

Intervention type: DRUG
Group type: OTHER
Intervention: Desipramine
Description: Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.

Intervention type: DRUG
Group type: OTHER
Intervention: Desipramine
Description: Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
Study: NCT01783704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUSH
Description: Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PULSE
Description: During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
Study: NCT03685539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Computed Tomography
Description: Undergo DECT
Study: NCT02121457

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazil nut
Description: Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Study: NCT04791774

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk protein (food grade protein)
Description: Subjects will receive an enteral nutritional formula containing 20 grams intrinsically labeled (1-\[13C\]-phenylalanine) milk protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fee amino acids (food grade amino acids)
Description: Nutritional formula containing 20 grams of a free amino acid mixture equivalent in composition to the milk protein with 1-\[13C\]-labeled phenylalanine
Study: NCT04450121

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be intubated using Air-Q airway
Description: Both groups:~Grade 1: Split airway provides an unobstructed path for bronchoscope from mouth to glottis.~Grade 2: Tongue rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 3: Epiglottis rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 4: Tongue and epiglottis rest against posterior pharyngeal wall, both causing partial obstruction to bronchoscope.~Grade 5: Tongue rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure).~Grade 6: Epiglottis rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be intubated using Air-Q airway
Description: Both groups:~Grade 1: Split airway provides an unobstructed path for bronchoscope from mouth to glottis.~Grade 2: Tongue rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 3: Epiglottis rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 4: Tongue and epiglottis rest against posterior pharyngeal wall, both causing partial obstruction to bronchoscope.~Grade 5: Tongue rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure).~Grade 6: Epiglottis rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure)
Study: NCT00864435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg Tablets, single dose
Description: A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coreg® 12.5 mg Tablets , single dose
Description: B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
Study: NCT02592239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional brain MRI
Description: Functional brain MRI before and after test meal ingestion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional brain MRI
Description: Functional brain MRI before and after test meal ingestion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A warm ham and cheese sandwich and a 200 ml fruit juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A warm ham and cheese sandwich and a 200 ml fruit juice
Study: NCT01131377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: If ABGA is pH ≥ 7.43 \& HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: They will receive saline 50ml via IV q 24h.
Study: NCT01748539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00775632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate or cyclosporine and methotrexate
Description: One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
Study: NCT02109484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 Subunit Vaccine 10mcg
Description: 10 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 Subunit Vaccine 10mcg
Description: 10 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 Subunit Vaccine 30 mcg
Description: 30 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 Subunit Vaccine 30 mcg
Description: 30 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 Subunit Vaccine 60mcg
Description: 60 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 Subunit Vaccine 60mcg
Description: 60 mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01296672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride 5mg every day by mouth for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every day by mouth for 3 months
Study: NCT01464060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI, amoxicillin, metronidazole and clarithromycin
Description: Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI, amoxicillin, metronidazole and clarithromycin
Description: Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
Study: NCT04602871

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath Biopsy
Description: Breath Biopsy sampling using the ReCIVA® Breath Sampler

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath Biopsy
Description: Breath Biopsy sampling using the ReCIVA® Breath Sampler
Study: NCT03742752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: administration of enteral nutrition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition
Description: administration of parenteral nutrition
Study: NCT02950467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: One individual oral psilocybin treatment session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified brief Supportive Expressive Group Therapy
Description: Ten sessions of twice-weekly manualized group therapy
Study: NCT02592057

Intervention type: DRUG
Intervention: SOF
Description: SOF tablets administered orally once daily based on approved prescribing information
Study: NCT04248491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL Emsella chair
Description: Subjects will sit on the device. The Research Nurse Coordinator (RNC) will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL Emsella chair
Description: Subjects will sit on the device. The Research Nurse Coordinator (RNC) will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.
Study: NCT03266016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Ventilator Protocol
Description: Computerized Decision Support System which recommends changes to ventilator settings to promote physiologic levels of patient effort of breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Ventilator Protocol
Description: Computerized Decision Support System which recommends changes to ventilator settings to promote physiologic levels of patient effort of breathing.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Esophageal Manometry
Description: Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Esophageal Manometry
Description: Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure
Study: NCT01157221

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a standardized physical therapy program
Description: passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: a standardized physical therapy program
Description: passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
Study: NCT03266016

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Esophageal Manometry
Description: Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Esophageal Manometry
Description: Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory Inductance Plethysmography (RIP)
Description: RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory Inductance Plethysmography (RIP)
Description: RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory Inductance Plethysmography (RIP)
Description: RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials
Study: NCT01157221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMSMTA
Description: end-range mobilization/scapular mobilization treatment approach
Study: NCT03266016

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory Inductance Plethysmography (RIP)
Description: RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials
Study: NCT01445951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin with MedTone C Inhaler
Description: Inhalation Powder and injectable insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere ®Insulin with Gen2 Inhaler
Description: Inhalation Powder and injectable insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart in combination with a basal insulin
Description: Injectable insulin
Study: NCT03020732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: test groups
Description: Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Concentrated growth factor(CGF) membranes were placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
Study: NCT03266016

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Diaphragm Ultrasound
Description: Daily measurement of diaphragm thickness and diaphragm contractile activity

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Diaphragm Ultrasound
Description: Daily measurement of diaphragm thickness and diaphragm contractile activity

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diaphragm Ultrasound
Description: Daily measurement of diaphragm thickness and diaphragm contractile activity

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diaphragm Ultrasound
Description: Daily measurement of diaphragm thickness and diaphragm contractile activity

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Maximal Inspiratory Pressure
Description: Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Maximal Inspiratory Pressure
Description: Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Maximal Inspiratory Pressure
Description: Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Maximal Inspiratory Pressure
Description: Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion
Study: NCT03020732

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control groups
Description: Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Subepithelial connective tissue graft was placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
Study: NCT02972073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Physical therapist will provide exercise for patients with low back pain for 60 minutes per day, 2-3 days per week for the total of 8 weeks.
Study: NCT03557892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM+CSII
Description: Animas Vibe Platinum insulin pump and Dexcom G4 CGM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MDI with degludec
Description: Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin
Study: NCT01271283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally
Study: NCT02342002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone for treatment of missed abortion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol for treatment of missed abortion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol for treatment of missed abortion